Biotransformation and Metabolite Elucidation of Xenobiotics: Characterization and Identification

CONTRIBUTORS.

1 HUMAN BIOTRANSFORMATION (Andrew Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffi ni N. Hensley, and Greg J. Loewen).

2 ANALYTICAL TOOLS AND APPROACHES FOR METABOLITE IDENTIFICATION IN DRUG METABOLISM (Yongmei Li).

3 TOOLS OF CHOICE FOR ACCELERATING METABOLITE IDENTIFICATION: MASS SPECTROMETRY TECHNOLOGY DRIVES METABOLITE IDENTIFICATION STUDIES FORWARD (Ala F. Nassar).

4 IMPROVING DRUG DESIGN: CONSIDERATIONS FOR THE STRUCTURAL MODIFICATION PROCESS (Ala F. Nassar).

5 CASE STUDY: THE UNANTICIPATED LOSS OF N₂ FROM NOVEL DNA ALKYLATING AGENT LAROMUSTINE BY COLLISION-INDUCED DISSOCIATION: NOVEL REARRANGEMENTS (Ala F. Nassar, Jing Du, David Roberts, Kevin Lin, Mike Belcourt, Ivan King, and TuKiet T. Lam).

6 CASE STUDY: IDENTIFICATION OF IN VITRO METABOLITE/DECOMPOSITION PRODUCTS OF THE NOVEL DNA ALKYLATING AGENT LAROMUSTINE (Ala F. Nassar, Jing Du, David Roberts, Kevin Lin, Mike Belcourt, Ivan King, and TuKiet T. Lam).

7 STRATEGIES FOR THE DETECTION OF REACTIVE INTERMEDIATES IN DRUG DISCOVERY AND DEVELOPMENT (Mark P. Grillo).

8 SAFETY TESTING OF DRUG METABOLITES: MIST GUIDANCE IMPACT ON THE PRACTICE OF INDUSTRIAL DRUG METABOLISM (J. Greg Slatter).

INDEX.